Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to Robust micelles formulation to improve systemic corticosteroid therapy in sepsis in multiple healthcare systems [Journal of controlled Release, Vol. 381, 10 May 2025, 113635].

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Chitosan-starch biodegradable hydrogels incorporating core-shell copper nanoparticles for complex wound healing.

International journal of biological macromolecules·2026
Same author

Polyelectrolyte complexation with biofunctionalized multivalent ions: Coarse-grained model and isothermal titration calorimetry experiment.

The Journal of chemical physics·2026
Same author

Development of a cationic bionanocomplex from N-aryl-chitosan derivatives for controlled drug release.

Carbohydrate polymers·2026
Same author

A Review of Radioactive Strontium for Radiation Protection Purposes.

Health physics·2026
Same author

Selective mRNA Delivery to Activated Macrophages via Hyaluronic Acid-Functionalized Lipid Nanoparticles with Optimized PEGylation.

Biomacromolecules·2026

Related Experiment Video

Updated: Jul 6, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Dexamethasone acetate encapsulation into Trojan particles.

Carolina Gómez-Gaete1, Elias Fattal, Lídia Silva

  • 1Univ Paris Sud, UMR CNRS 8612, Faculté de Pharmacie, Châtenay-Malabry, France.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|April 1, 2008
PubMed
Summary
This summary is machine-generated.

Trojan particles combine nanoparticle and microparticle advantages for drug delivery. This novel system effectively slows dexamethasone release for potential intravitreal therapies.

More Related Videos

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Related Experiment Videos

Last Updated: Jul 6, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Area of Science:

  • Biomaterials Science
  • Drug Delivery Systems
  • Ophthalmic Pharmaceuticals

Background:

  • Nanoparticle systems offer therapeutic potential but can be difficult to handle.
  • Microparticles provide ease of manipulation for drug delivery applications.
  • Intravitreal administration requires sophisticated delivery vehicles for sustained drug release.

Purpose of the Study:

  • To develop and characterize a novel hybrid delivery vehicle, Trojan particles, for intravitreal dexamethasone administration.
  • To optimize the encapsulation of dexamethasone acetate (DXA) into poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles.
  • To evaluate the physical characteristics and drug release profile of Trojan particles.

Main Methods:

  • Dexamethasone acetate (DXA) encapsulation into PLGA nanoparticles.
  • Formulation of Trojan particles via spray drying using 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) and hyaluronic acid (HA).
  • Characterization using SEM, confocal microscopy, and in vitro drug release studies under sink conditions.

Main Results:

  • Trojan particles were predominantly spherical and hollow with irregular surfaces due to nanoparticle presence.
  • Nanoparticle concentration did not significantly alter Trojan particle size distribution or tap density.
  • Spray drying led to a significant increase in nanoparticle size, while the matrix protected nanoparticles, slowing DXA release.

Conclusions:

  • Trojan particles represent a promising hybrid delivery system combining nanoparticle therapeutic benefits with microparticle handling ease.
  • The spray-dried excipient matrix in Trojan particles effectively modulates dexamethasone release, suggesting potential for sustained ophthalmic drug delivery.
  • Further investigation into Trojan particles for intravitreal dexamethasone delivery is warranted based on promising in vitro release profiles.